Welcome to our dedicated page for Becton Dickinson & news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & stock.
Becton, Dickinson and Company reports developments for a global medical technology business organized around medical essentials, connected care, biopharma systems and interventional products. Company news commonly covers fiscal results, guidance, dividends, share repurchases, debt retirement, executive appointments and strategy updates following the completed separation of the Biosciences and Diagnostic Solutions business.
BD updates also include product and customer developments across its care-delivery platforms. Recent themes include the BD® CentroVena One™ Insertion System for central venous catheter placement, BD Pyxis™ Pro medication dispensing technologies, BD Alaris™ Infusion Systems, vascular access products, medication management, patient-safety workflows and partnerships with health systems.
BD (Becton, Dickinson and Company) has received CE marking for its BD MAX™ Respiratory Viral Panel (RVP), a diagnostic test that detects SARS-CoV-2, Influenza A + B, and RSV using a single nasal or nasopharyngeal swab. This test enhances diagnostic efficiency, crucial during flu season, by enabling quick differentiation and treatment for these viruses. The BD MAX™ System, which supports this assay, is widely utilized globally for various diagnostic tests. BD plans to seek Emergency Use Authorization from the FDA shortly.
BD (Becton, Dickinson and Company) has announced a voluntary recall of certain lots of Intraosseous Needle Set Kits, Manual Driver Kits, and Powered Drivers. The recall is due to potential issues that could lead to difficulty in needle assembly removal, failure of safety mechanisms, and functional loss of intraosseous access. These defects may cause delays in patient care or increase the risk of needlestick injuries. BD advises customers to review their inventory and temporarily halt usage until further notice.
BD (Becton, Dickinson and Company) announced a collaboration with Mayo Clinic Platform to access a vast collection of de-identified clinical data to enhance post-market surveillance of its products. This partnership aims to accelerate innovation, improve patient care, and leverage real-world data for insights beyond traditional clinical trials.
The Mayo Clinic Platform offers access to data from 10 million patients, including extensive lab results and clinical notes. BD plans to utilize advanced analytics and predictive modeling to enhance product development and regulatory submissions, ultimately improving patient outcomes.
CerTest Biotec and BD (Becton, Dickinson and Company) (NYSE: BDX) have partnered to develop a RT-PCR detection kit for the Monkeypox virus using the BD MAX™ Molecular Diagnostic System. This collaboration aims to leverage the BD MAX™ open system reagent suite to validate the CerTest VIASURE Monkeypox CE/IVD test, enhancing user access to confirmatory testing. The BD MAX™ System can process up to 24 samples in under three hours, streamlining diagnostics for various infections.
BD (Becton, Dickinson and Company) has appointed Simon Campion as the new executive vice president and president of its Medical segment, effective July 1, 2022. Campion, who has extensive experience with BD and previously led the Interventional segment, succeeds Alberto Mas who is retiring. His role will focus on the operational and commercial performance of the Medical segment, aligned with BD’s 2025 strategy. Campion holds a Ph.D. in Mechanical Engineering and an MBA.
BD (Becton, Dickinson and Company) has announced its acquisition of Parata Systems for $1.525 billion. This move aims to expand BD's pharmacy automation technologies across various healthcare settings, including hospitals and retail pharmacies. The acquisition is projected to enhance BD's revenue growth, adjusted operating margins, and adjusted earnings per share immediately. Parata's market, valued at $600 million and expected to grow by 10% annually, aligns with BD's 2025 strategy for smart, connected care.
BD (Becton, Dickinson and Company) (NYSE: BDX) has launched the BD FACSDiscover™ S8 Cell Sorter featuring revolutionary BD CellView™ Image Technology at the ISAC CYTO 2022 conference. This new technology allows researchers to sort and view cells rapidly and accurately, enhancing research in virology, oncology, and other fields. The sorter combines spectral flow cytometry with detailed image analysis, enabling previously unidentifiable cell sorting. This development aims to redefine standards in cell sorting, potentially accelerating medical discoveries and therapeutic advancements.
BD (Becton, Dickinson and Company) announced its presentation at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 16, 2022, at 11:00 a.m. Eastern Time. The live webcast will be accessible via the BD investor relations website, with a replay available post-event. As a leading global medical technology company, BD focuses on improving medical discovery and care delivery, supported by a dedicated workforce of 75,000 employees worldwide.
BD has received 510(k) clearance from the FDA for its BD COR™ MX instrument, enhancing STI diagnostics capabilities. The first assay available detects Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. This system automates laboratory workflows, enabling the processing of 1,700 specimens and delivering up to 1,000 results in 24 hours. By reducing manual interactions, it aims to alleviate staff workloads, especially critical amidst ongoing healthcare staffing challenges. Future assays for women's health and other indications are in development.
Babson Diagnostics and BD (Becton, Dickinson and Company) have expanded their partnership to enhance blood sample collection, making it more patient-centered and less invasive. Announced on May 11, 2022, the collaboration aims to enable at-home blood sample collection and broaden test capabilities to include pediatric diagnostics. This initiative, developed since 2019, leverages advanced capillary collection technology, requiring only a fraction of the blood volume compared to traditional methods. The companies aim to improve patient compliance by providing a more convenient testing experience.